Skip to main content

Table 3 Patient characteristics

From: Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study

CRF # Age (years) Time since first diagnosis of SLE Time since first diagnosis of nephritis LN-WHO type Pre-treatment of LN within six months before study start
9 20 1.5 years 1.5 years IV Prednisone, AZA, MMF, HCQ
10 34 2.5 years 2.5 years IV CYC, AZA, Prednisone
11 46 11 years 11 years IV Prednisone, MMF
13 39 8. 5 years 4 years V Prednisone, MMF
14 20 2 years 4 years IV MMF
15 37 7 years 7 years IV CYC, Prednisone, CSA, AZA
16 30 17 years 17 years IV Prednisone,
17 40 21.5 years 21.5 years III AZA, Prednisone, MMF, Immunadsorption
19 20 4.5 years 4.5 years IV AZA, MMF, Prednisone, Methylprednisolon, HCQ, Rituximab, Octagam
26 35 9 years 8 years IV Prednisone, MMF
31 22, 5 3 years 3 years IV CYC, Prednisone
32 42 12 years 12 years V AZA, Methylprednisolon
33 31 7 years 7 years IV MMF, Prednisone, HCQ
34 19 1 year 1 year IV AZA, CYC, Prednison
35 42 10.5 years 10.5 years IV Prednisone, AZA
36 30 13 years 4 years IV Methylprednisolon AZA
38 22 2.5 years 2.5 years IV CYC, Prednisone, HCQ
39 46 2 years 2 years IV HCQ, plasmapheresis Prednisolone
42 29 10 years 1 year V Prednisone, CSA
49 37, 5 4 years 4 years V Prednisone, CSA
50 20 1 year 1 year IV Prednisone, AZA, MMF, CYC, Prednisone
  1. AZA, azathioprin; CRF, case report form; CSA, cyclosporine A; CYC, cyclophosphamide; HCQ, hydroxychloroquine; LN, lupus nephritis; MMF, mycophenolic acid; SLE, systemic lupus erythematosus.